Novo Nordisk, the Danish drugmaker behind famed weight-loss drugs Wegovy and Ozempic, is leading the way in the semaglutide trend. 

The drugs help people lose weight, but they've also proven to be helpful in reducing health conditions like heart disease and kidney disease.

CEO Mike Doustdar says more people are starting to recognise that Novo Nordisk's output goes beyond an agent that reduces sugar for diabetics. 

"It has some very serious health benefits around it, be it cardiovascular protection, liver protection, kidney protection - and more to be tested. So it's a breakthrough innovation." 

LISTEN ABOVE

Novo Nordisk, the Danish drugmaker behind famed weight-loss drugs Wegovy and Ozempic, is leading the way in the semaglutide trend.&nbsp;
The drugs help people lose weight, but they've also proven to be helpful in reducing health conditions like heart disease and kidney disease.
CEO Mike Doustdar says more people are starting to recognise that Novo Nordisk's output goes beyond an agent that reduces sugar for diabetics.&nbsp;
"It has some very serious health benefits around it, be it cardiovascular protection, liver protection, kidney protection - and more to be tested. So it's a breakthrough innovation."&nbsp;
LISTEN ABOVE

With a straight down the middle approach, Heather du Plessis-Allan Drive on Newstalk ZB delivers the very latest news and views to New Zealanders as they wrap up their day.

Heather du Plessis-Allan Drive

Mike Doustdar: Novo Nordisk CEO on the company's developments in weight-loss drugs

https://api.omny.fm/orgs/7784f840-c291-422a-924b-ad9000bbad71/clips/d858d055-573e-4a0f-87f1-b4120062f628/transcript